Search results
Antibody discovery promises new hope in influenza B battle, paves way for universal vaccine
Medical Xpress· 3 days agoSeasonal flu vaccines cover influenza B and the more common influenza A but do not stimulate the broadest possible range of immune responses against both viruses. In addition, people whose immune ...
Novel vaccine concept generates immune responses that could produce multiple types of HIV...
Medical Xpress· 5 days agoUsing a combination of cutting-edge immunologic technologies, researchers have successfully...
'Smart warheads' of cancer: Experts' excitement for treatment approach grows
Becker’s Hospital Review· 2 days agoCancer experts are increasingly optimistic about the potential for antibody-drug conjugates to become a standard treatment approach. The therapies involve attaching chemotherapy ...
How antibody–drug conjugates aim to take down cancer
Nature· 7 days agoScientists are trying to work out how to balance potency with toxicity and tackle the cost of next-generation therapeutics.
Antibodies may aid effort to fight influenza B: st | Newswise
Newswise· 5 days agoResearchers at Vanderbilt University Medical Center have isolated human monoclonal antibodies against influenza B, a significant public health threat that disproportionately affects children ...
Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC
Clinical Trials Arena via Yahoo Finance· 1 day agoGenmab and BioNTech announced the initial data from the phase II GCT1046-04 trial, which evaluated...
Vaccination induces broadly neutralizing antibody precursors to HIV gp41 - Nature Immunology
Nature· 6 days agoSchief and colleagues show that germline-targeting epitope scaffolds can elicit responses from rare broadly neutralizing antibody precursor B cells with predefined binding specificities and genetic features.
Leonard Schleifer
Fortune· 7 hours agoRegeneron is a research-oriented biotech, founded by Schleifer, that had no product on the market for its first 20 years. Today its monoclonal antibodies, particularly Eylea for retinal diseases ...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
Digital Journal· 1 day agoBriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of & ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoMerus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ...
